RT Journal Article
SR Electronic
T1 Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e003580
DO 10.1136/jitc-2021-003580
VO 9
IS 12
A1 Shah, Manish A
A1 Cunningham, David
A1 Metges, Jean-Philippe
A1 Van Cutsem, Eric
A1 Wainberg, Zev
A1 Elboudwarej, Emon
A1 Lin, Kai-Wen
A1 Turner, Scott
A1 Zavodovskaya, Marianna
A1 Inzunza, David
A1 Liu, Jinfeng
A1 Patterson, Scott D
A1 Zhou, Jingzhu
A1 He, Jing
A1 Thai, Dung
A1 Bhargava, Pankaj
A1 Brachmann, Carrie Baker
A1 Cantenacci, Daniel V T
YR 2021
UL http://jitc.bmj.com/content/9/12/e003580.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.